Abstract
Interleukin-4 (IL4) is a Th2 cytokine that can signal through two different receptors, one of which—the type II receptor—is overexpressed by various cancer cells. Previously, we have shown that type II IL4 receptor signaling increases proliferation and metastasis in mouse models of breast cancer, as well as increasing glucose and glutamine metabolism. Here, we expand on those findings to determine mechanistically how IL4 signaling links glucose metabolism and histone acetylation to drive proliferation in the context of triple-negative breast cancer (TNBC). We used a combination of cellular, biochemical, and genomics approaches to interrogate TNBC cell lines, which represent a cancer type where high expression of the type II IL4 receptor is linked to reduced survival. Our results indicate that type II IL4 receptor activation leads to increased glucose uptake, Akt and ACLY activation, and histone acetylation in TNBC cell lines. Inhibition of glucose uptake through the deletion of Glut1 ablates IL4-induced proliferation. Additionally, pharmacological inhibition of histone acetyltransferase P300 attenuates IL4-mediated gene expression and proliferation in vitro. Our work elucidates a role for type II IL4 receptor signaling in promoting TNBC progression, and highlights type II IL4 signaling, as well as histone acetylation, as possible targets for therapy.
Funding Information
  • Office of the Secretary of Defense (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
  • National Cancer Institute (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
  • NRSA F31 Award (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
  • National Cancer Institute (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
  • National Institutes of Health (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
  • National Institutes of Health (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
  • National Eye Institute (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
  • National Institutes of Health (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)

This publication has 67 references indexed in Scilit: